PURPOSE: Hepatitis C virus (HCV) viral relapse (VR) after end-of-treatment response (ETR) in human immunodeficiency virus (HIV) co-infected patients is observed in as many as one in three co-infected patients. The aim of the study was to identify baseline risk factors for VR in HIV/HCV co-infected patients treated with pegylated interferon plus ribavirin (PEG-INF/RBV). METHODS: A total of 212 Caucasian HIV-infected patients with chronic hepatitis C naïve for PEG-INF/RBV were followed prospectively. Patients were included in this prospective study if they had completed a full course of therapy with an ETR. We assessed the relationship between VR rate and potential predictors of relapse. RESULTS: Of the patients followed, 130 (61.3 %) attained ETR and 103 (79.2 %) achieved sustained virological response (SVR). Consequently, 27 (20.8 %) showed VR. Patients who relapsed were more often male (p = 0.036), carried the non-CC rs14158 genotype in the low-density lipoprotein receptor (LDLr) gene (p = 0.039), had higher baseline HCV RNA levels (p = 0.012), body mass index (BMI) ≥ 25 kg/m(2) (p = 0.034), significant liver fibrosis (p < 0.001), had been diagnosed with acquired immunodeficiency syndrome (AIDS)-defining criteria in the past (p = 0.001) and bore the HCV genotypes 1/4 (p = 0.046) when compared with SVR patients. The IL28B genotype was not associated with relapse. Multivariate binary logistic regression showed that high baseline HCV RNA, significant liver fibrosis, HCV genotypes 1/4, being overweight and being diagnosed with AIDS-defining criteria in the past were independently associated with relapse. CONCLUSIONS: Our study shows that VR can be accurately predicted in HIV/HCV co-infected patients on the basis of risk factors which can be identified before treatment.
PURPOSE:Hepatitis C virus (HCV) viral relapse (VR) after end-of-treatment response (ETR) in human immunodeficiency virus (HIV) co-infectedpatients is observed in as many as one in three co-infected patients. The aim of the study was to identify baseline risk factors for VR in HIV/HCV co-infectedpatients treated with pegylated interferon plus ribavirin (PEG-INF/RBV). METHODS: A total of 212 Caucasian HIV-infectedpatients with chronic hepatitis C naïve for PEG-INF/RBV were followed prospectively. Patients were included in this prospective study if they had completed a full course of therapy with an ETR. We assessed the relationship between VR rate and potential predictors of relapse. RESULTS: Of the patients followed, 130 (61.3 %) attained ETR and 103 (79.2 %) achieved sustained virological response (SVR). Consequently, 27 (20.8 %) showed VR. Patients who relapsed were more often male (p = 0.036), carried the non-CC rs14158 genotype in the low-density lipoprotein receptor (LDLr) gene (p = 0.039), had higher baseline HCV RNA levels (p = 0.012), body mass index (BMI) ≥ 25 kg/m(2) (p = 0.034), significant liver fibrosis (p < 0.001), had been diagnosed with acquired immunodeficiency syndrome (AIDS)-defining criteria in the past (p = 0.001) and bore the HCV genotypes 1/4 (p = 0.046) when compared with SVR patients. The IL28B genotype was not associated with relapse. Multivariate binary logistic regression showed that high baseline HCV RNA, significant liver fibrosis, HCV genotypes 1/4, being overweight and being diagnosed with AIDS-defining criteria in the past were independently associated with relapse. CONCLUSIONS: Our study shows that VR can be accurately predicted in HIV/HCV co-infectedpatients on the basis of risk factors which can be identified before treatment.
Authors: Juan A Pineda; Antonio Caruz; Federico A Di Lello; Angela Camacho; Pilar Mesa; Karin Neukam; Antonio Rivero-juárez; Juan Macías; Jesús Gómez-Mateos; Antonio Rivero Journal: AIDS Date: 2011-07-17 Impact factor: 4.177
Authors: Alexander J Thompson; Andrew J Muir; Mark S Sulkowski; Dongliang Ge; Jacques Fellay; Kevin V Shianna; Thomas Urban; Nezam H Afdhal; Ira M Jacobson; Rafael Esteban; Fred Poordad; Eric J Lawitz; Jonathan McCone; Mitchell L Shiffman; Greg W Galler; William M Lee; Robert Reindollar; John W King; Paul Y Kwo; Reem H Ghalib; Bradley Freilich; Lisa M Nyberg; Stefan Zeuzem; Thierry Poynard; David M Vock; Karen S Pieper; Keyur Patel; Hans L Tillmann; Stephanie Noviello; Kenneth Koury; Lisa D Pedicone; Clifford A Brass; Janice K Albrecht; David B Goldstein; John G McHutchison Journal: Gastroenterology Date: 2010-04-24 Impact factor: 22.682
Authors: Wendy S C Cheng; Stuart K Roberts; Geoffrey McCaughan; William Sievert; Martin Weltman; Darrell Crawford; William Rawlinson; Philippa S Marks; James Thommes; Bishoy Rizkalla; Motoko Yoshihara; Gregory J Dore Journal: J Hepatol Date: 2010-06-16 Impact factor: 25.083
Authors: Juan A Pineda; Antonio Caruz; Antonio Rivero; Karin Neukam; Irene Salas; Angela Camacho; José C Palomares; José A Mira; Antonio Martínez; Carmen Roldán; Julián de la Torre; Juan Macías Journal: Clin Infect Dis Date: 2010-10-01 Impact factor: 9.079
Authors: José Medrano; Pablo Barreiro; Salvador Resino; Paula Tuma; Violeta Rodríguez; Eugenia Vispo; Pablo Labarga; Antonio Madejón; Javier García-Samaniego; Inmaculada Jiménez-Nácher; Luz Martín-Carbonero; Vincent Soriano Journal: Clin Infect Dis Date: 2009-11-01 Impact factor: 9.079
Authors: Thijs J W van de Laar; Richard Molenkamp; Charlotte van den Berg; Janke Schinkel; Marcel G H M Beld; Maria Prins; Roel A Coutinho; Sylvia M Bruisten Journal: J Hepatol Date: 2009-06-18 Impact factor: 25.083
Authors: Monica Basso; Marzia Franzetti; Renzo Scaggiante; Andrea Sattin; Carlo Mengoli; Mario Cruciani; Marta Fiscon; Giorgio Palù; Saverio Giuseppe Parisi Journal: AIDS Res Ther Date: 2014-07-29 Impact factor: 2.250